LisenID and ChristianaCare team up in a research collaboration

Wilmington, Del. — July 4th, 2026 — Lisen Imprinting Diagnostics (LisenID), a precision diagnostics company pioneering the clinical application of Loss of Imprinting (LOI) as an early molecular biomarker for cancer, announced on June 15th 2026 a research collaboration with ChristianaCare’s Cawley Center for Translational Cancer Research to evaluate its proprietary QCIGISH (Quantitative Chromogenic Imprinted Gene […]

Read More

LisenID graduates from 2025/2026 Creative Destruction Lab Cancer Stream

Wilmington, DE and Toronto, ON – July 2026 — Lisen Imprinting Diagnostics (LisenID), a cancer diagnostics startup pioneering the use of Loss of Imprinting (LOI) as an early biomarker for cancer, announced its graduation from the 2025/2026 Cancer Stream of the Creative Destruction Lab (CDL) in May 2026, a highly selective, objectives-based program for science-driven […]

Read More